No significant strengths identified
| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| TECHBio-Techne Corporation | 10.9B | 69.96 | 152.09 | 5.23% | 6.41% | 3.97% | 2.35% | 0.23 |
| SPRYARS Pharmaceuticals, Inc. | 1.1B | 11.09 | 142.00 | 2970.63% | -56.06% | -54.21% | 1.18% | 0.00 |
| VCYTVeracyte, Inc. | 3.24B | 41.00 | 132.26 | 23.46% | 6.12% | 2.41% | 1.97% | 0.04 |
| CSBRChampions Oncology, Inc. | 99.56M | 7.17 | 21.73 | 13.54% | 4.32% | 59.65% | 7.03% | 1.62 |
| MDXGMiMedx Group, Inc. | 851.59M | 5.75 | 20.54 | 8.52% | 10.38% | 17.09% | 7.58% | 0.13 |
| LTRNLantern Pharma Inc. | 39.26M | 3.51 | -0.00 | -197.36% | 0.01 | |||
| SEERSeer, Inc. | 107.44M | 1.91 | -1.37 | -8.13% | -486.02% | -29.19% | 0.08 | |
| IMDXInsight Molecular Diagnostics Inc. | 189.76M | 6.62 | -1.42 | 25.15% | -13.81% | -14.81% |
| Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 | |
|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - |
| Cost of Goods Sold | 391.42K | 0 | 0 | 0 | 129.09K |
| COGS % of Revenue | - | - | - | - | - |
| Gross Profit | -391.42K | 0 | 0 | 0 | -129.09K |
| Gross Margin % | - | - | - | - | - |
| Gross Profit Growth % | - | 1% | - | - | - |
| Operating Expenses | 23.01M | 116.08M | 38.56M | 81.64M | 188.97M |
| OpEx % of Revenue | - | - | - | - | - |
| Selling, General & Admin | 7.47M | 14.33M | 15.32M | 24.56M | 17.88M |
| SG&A % of Revenue | - | - | - | - | - |
| Research & Development | 15.54M | 8.37M | 4.17M | 2.71M | 537.43K |
| R&D % of Revenue | - | - | - | - | - |
| Other Operating Expenses | 0 | 93.38M | 19.07M | 54.37M | 170.55M |
| Operating Income | -23.4M | -116.08M | -38.56M | -81.64M | -188.97M |
| Operating Margin % | - | - | - | - | - |
| Operating Income Growth % | - | -3.96% | 0.67% | -1.12% | -1.31% |
| EBITDA | -23.01M | -115.96M | -38.44M | -81.52M | -188.84M |
| EBITDA Margin % | - | - | - | - | - |
| EBITDA Growth % | - | -4.04% | 0.67% | -1.12% | -1.32% |
| D&A (Non-Cash Add-back) | 391.42K | 123.59K | 113.5K | 121.86K | 129.09K |
| EBIT | -26.47M | -113.06M | -38.98M | -85.99M | -177.28M |
| Net Interest Income | -366.43K | -250.8K | -706.96K | -2.43M | -609.34K |
| Interest Income | 13.18K | 122.04K | 0 | 0 | 116.35K |
| Interest Expense | 379.61K | 372.84K | 706.96K | 2.43M | 725.68K |
| Other Income/Expense | -3.45M | 2.65M | -1.13M | -6.79M | 10.96M |
| Pretax Income | -26.85M | -113.43M | -39.68M | -88.43M | -178.01M |
| Pretax Margin % | - | - | - | - | - |
| Income Tax | -125.28K | 34 | 0 | 0 | 0 |
| Effective Tax Rate % | 1% | 1% | 1% | 1% | 1% |
| Net Income | -26.72M | -113.43M | -39.68M | -88.43M | -178.01M |
| Net Margin % | - | - | - | - | - |
| Net Income Growth % | - | -3.24% | 0.65% | -1.23% | -1.01% |
| Net Income (Continuing) | -26.72M | -113.43M | -39.68M | -88.43M | -178.01M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -5.67 | -21.60 | -7.10 | -9.10 | -10.78 |
| EPS Growth % | - | -2.81% | 0.67% | -0.28% | -0.18% |
| EPS (Basic) | -5.67 | -21.60 | -7.10 | -9.10 | -10.78 |
| Diluted Shares Outstanding | 4.72M | 5.25M | 5.63M | 9.75M | 16.51M |
| Basic Shares Outstanding | 4.72M | 5.25M | 5.63M | 9.75M | 16.51M |
| Dividend Payout Ratio | - | - | - | - | - |
| Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 | |
|---|---|---|---|---|---|
| Total Current Assets | 20.9M | 9.57M | 2.57M | 2M | 1.05M |
| Cash & Short-Term Investments | 20.66M | 9.17M | 1.87M | 220.47K | 480.55K |
| Cash Only | 20.66M | 9.17M | 1.87M | 220.47K | 92.7K |
| Short-Term Investments | 0 | 0 | 0 | 0 | 387.85K |
| Accounts Receivable | 1.64K | 0 | 0 | 1.11M | 0 |
| Days Sales Outstanding | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - |
| Other Current Assets | 0 | 393K | 690.92K | 668.93K | 566.08K |
| Total Non-Current Assets | 168.71M | 75.07M | 55.74M | 161.13M | 7.18M |
| Property, Plant & Equipment | 2.16M | 1.74M | 1.42M | 1.75M | 1.06M |
| Fixed Asset Turnover | - | - | - | - | - |
| Goodwill | 11.64M | 11.64M | 11.64M | 159.33M | 5.96M |
| Intangible Assets | 154.89M | 61.62M | 42.65M | 30.04K | 165.99K |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 20.98K | 68.64K | 21.74K | 19.85K | 0 |
| Total Assets | 189.61M | 84.63M | 58.3M | 163.13M | 8.23M |
| Asset Turnover | - | - | - | - | - |
| Asset Growth % | - | -0.55% | -0.31% | 1.8% | -0.95% |
| Total Current Liabilities | 1.89M | 6.45M | 11.02M | 30.31M | 29.16M |
| Accounts Payable | 320.56K | 1.4M | 5.3M | 9.45M | 12.56M |
| Days Payables Outstanding | 298.93 | - | - | - | 35.5K |
| Short-Term Debt | 353.01K | 1.2M | 4.62M | 2.45M | 9.44M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 1.21M | 2.56M | 184.73K | 12.61M | 1.01M |
| Current Ratio | 11.08x | 1.48x | 0.23x | 0.07x | 0.04x |
| Quick Ratio | 11.08x | 1.48x | 0.23x | 0.07x | 0.04x |
| Cash Conversion Cycle | - | - | - | - | - |
| Total Non-Current Liabilities | 13.06M | 5.56M | 775.59K | 842.39K | 424.55K |
| Long-Term Debt | 5.78M | 4.58M | 0 | 0 | 0 |
| Capital Lease Obligations | 1.24M | 985.7K | 775.59K | 842.39K | 424.55K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 6.04M | 0 | 0 | 0 | 0 |
| Total Liabilities | 14.94M | 12.01M | 11.8M | 31.15M | 29.58M |
| Total Debt | 7.37M | 7.02M | 5.59M | 3.79M | 10.17M |
| Net Debt | -13.29M | -2.16M | 3.72M | 3.57M | 10.08M |
| Debt / Equity | 0.04x | 0.10x | 0.12x | 0.03x | - |
| Debt / EBITDA | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - |
| Interest Coverage | -61.65x | -311.33x | -54.54x | -33.53x | -260.40x |
| Total Equity | 174.66M | 72.62M | 46.5M | 131.98M | -21.35M |
| Equity Growth % | - | -0.58% | -0.36% | 1.84% | -1.16% |
| Book Value per Share | 37.03 | 13.82 | 8.26 | 13.53 | -1.29 |
| Total Shareholders' Equity | 174.66M | 72.62M | 46.5M | 131.98M | -21.35M |
| Common Stock | 5.22K | 5.3K | 6.37K | 15.85K | 17.74K |
| Retained Earnings | -90.91M | -204.35M | -244.03M | -332.46M | -510.46M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -10.83K | -30.44K | -29.88K | -170.85K | 10.81M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 | |
|---|---|---|---|---|---|
| Cash from Operations | -20.61M | -15.73M | -11.77M | -10.97M | -7.87M |
| Operating CF Margin % | - | - | - | - | - |
| Operating CF Growth % | - | 0.24% | 0.25% | 0.07% | 0.28% |
| Net Income | -26.72M | -113.43M | -39.68M | -88.43M | -178.01M |
| Depreciation & Amortization | 391.42K | 123.59K | 113.5K | 121.86K | 129.09K |
| Stock-Based Compensation | 0 | 5.49M | 3.54M | 4.67M | 3.31M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 4.79M | 90.67M | 19.96M | 63.85M | 160.83M |
| Working Capital Changes | 932.13K | 1.42M | 4.31M | 8.81M | 5.86M |
| Change in Receivables | 342 | 1.59K | 46 | -1.11M | 1.15M |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -272.32K | 1.08M | 3.89M | 4.06M | 3.11M |
| Cash from Investing | -48.89K | -5.16K | -29.77K | -1.26M | -500K |
| Capital Expenditures | -48.89K | -5.16K | -29.77K | -70.43K | 0 |
| CapEx % of Revenue | - | - | - | - | - |
| Acquisitions | - | - | - | - | - |
| Investments | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 32.6M | 4.25M | 4.52M | 10.52M | 8.38M |
| Debt Issued (Net) | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - |
| Other Financing | 1.22M | 134.91K | 503.23K | -528.21K | -971.23K |
| Net Change in Cash | - | - | - | - | - |
| Free Cash Flow | -20.66M | -15.74M | -11.8M | -11.04M | -7.87M |
| FCF Margin % | - | - | - | - | - |
| FCF Growth % | - | 0.24% | 0.25% | 0.06% | 0.29% |
| FCF per Share | -4.38 | -3.00 | -2.10 | -1.13 | -0.48 |
| FCF Conversion (FCF/Net Income) | 0.77x | 0.14x | 0.30x | 0.12x | 0.04x |
| Interest Paid | 0 | 79.72K | 352.33K | 20.13K | 24.55K |
| Taxes Paid | 0 | 34 | 0 | 0 | 0 |
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Return on Equity (ROE) | -15.3% | -91.74% | -66.63% | -99.09% | -321.81% |
| Return on Invested Capital (ROIC) | -10.88% | -75.11% | -47.92% | -65.92% | -228.08% |
| Debt / Equity | 0.04x | 0.10x | 0.12x | 0.03x | - |
| Interest Coverage | -61.65x | -311.33x | -54.54x | -33.53x | -260.40x |
| FCF Conversion | 0.77x | 0.14x | 0.30x | 0.12x | 0.04x |
Lunai Bioworks Inc. (LNAI) grew revenue by 0.0% over the past year. Growth has been modest.
Lunai Bioworks Inc. (LNAI) reported a net loss of $131.0M for fiscal year 2024.
Lunai Bioworks Inc. (LNAI) has a return on equity (ROE) of -321.8%. Negative ROE indicates the company is unprofitable.
Lunai Bioworks Inc. (LNAI) had negative free cash flow of $7.2M in fiscal year 2024, likely due to heavy capital investments.